Results 11 to 20 of about 198,722 (342)

Mutations of the BRAF gene in human cancer [PDF]

Nature, 2002
Cancers arise owing to the accumulation of mutations in critical genes that alter normal programmes of cell proliferation, differentiation and death. As the first stage of a systematic genome-wide screen for these genes, we have prioritized for analysis ...
Bignell, G.R., Bigner, D.D., Bottomley, W., Chenevix-Trench, G., Clegg, S., Cooper, C., Cossu, A., Cox, C., Darrow, T.L., Davies, H., Davis, N., Dicks, E., Edkins, S., Ewing, R., Flanagan, A., Floyd, Y., Futreal, P.A., Garnett, M.J., Gray, K., Gusterson, B.A., Hall, S., Hargrave, D., Hawes, R., Ho, J.W.C., Hooper, S., Hughes, J., Jayatilake, H., Kosmidou, V., Leung, S.Y., Maitland, N., Marais, R., Marshall, C.J., Menzies, A., Mould, C., Nicholson, A., Palmieri, G., Parker, A., Paterson, H., Pritchard-Jones, K., Riggins, G.J., Seigler, H.F., Shipley, J., Stephens, P., Stevens, C., Stratton, M.R., Teague, J., Watt, S., Weber, B.L., Wilson, R., Woffendin, H., Wooster, R., Yuen, S.T.   +51 more
core   +2 more sources

Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial

Nature Medicine, 2023
While BRAF inhibitor combinations with EGFR and/or MEK inhibitors have improved clinical efficacy in BRAF^V600E colorectal cancer (CRC), response rates remain low and lack durability. Preclinical data suggest that BRAF/MAPK pathway inhibition may augment
Jun Tian, Jonathan H. Chen, S. Chao, K. Pelka, M. Giannakis, J. Hess, K. Burke, Vjola Jorgji, Princy Sindurakar, Jonathan Braverman, Arnav Mehta, Tomonori Oka, Mei Huang, David J. Lieb, Maxwell Spurrell, Jill N. Allen, T. Abrams, Jeffrey W. Clark, A. Enzinger, P. Enzinger, S. Klempner, N. McCleary, J. Meyerhardt, D. Ryan, M. Yurgelun, K. Kanter, Emily E. Van Seventer, I. Baiev, Gary Chi, Joy Jarnagin, W. Bradford, Edmond Wong, Alexa G Michel, Isobel J. Fetter, G. Siravegna, A. Gemma, A. Sharpe, S. Demehri, R. Leary, C. D. Campbell, Omer H. Yilmaz, G. Getz, A. Parikh, N. Hacohen, R. Corcoran   +44 more
semanticscholar   +1 more source

BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers

Cancers, 2023
Simple Summary Cutaneous melanoma represents the most aggressive form of skin cancer and its occurrence, development, and progression are based on the accumulation of several genetic alterations.
G. Castellani, Mariachiara Buccarelli, Maria Beatrice Arasi, S. Rossi, M. Pisanu, M. Bellenghi, C. Lintas, C. Tabolacci   +7 more
semanticscholar   +1 more source

Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAFV600E Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study

Thyroid, 2023
Background: The aim of this study was to describe the oncologic outcomes of patients with BRAFV600E-mutated anaplastic thyroid cancer (ATC) who had neoadjuvant BRAF-directed therapy with subsequent surgery.
Xiao Zhao, J. Wang, R. Dadu, N. Busaidy, Lei Xu, K. Learned, N. Chasen, T. Vu, A. Maniakas, Arturo Eguia, J. Diersing, N. Gross, R. Goepfert, S. Lai, M. Hofmann, R. Ferrarotto, Charles Lu, G. Gunn, M. Spiotto, V. Subbiah, Michelle D Williams, M. Cabanillas, M. Zafereo   +22 more
semanticscholar   +1 more source

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy

ESMO Open, 2023
BRAF activation occurs as part of the mitogen-activated protein kinase (MAPK) cellular signaling pathway which leads to increased cellular proliferation and survival.
M. Gouda, V. Subbiah
semanticscholar   +1 more source

Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments.

Annals of Oncology, 2023
BACKGROUND Combination of a BRAF inhibitor (BRAFi) and an anti-EGFR, with or without a MEK inhibitor (MEKi) improves survival in BRAF-V600E-mutant metastatic colorectal cancer (mCRC) over standard chemotherapy.
J. Ros, J. Matito, G. Villacampa, R. Comas, A. García, G. Martini, I. Baraibar, N. Saoudi, F. Salvà, A. Martin, M. Antista, R. Toledo, E. Martinelli, F. Pietrantonio, A. Boccaccino, C. Cremolini, R. Dientsmann, J. Tabernero, A. Vivancos, E. Élez   +19 more
semanticscholar   +1 more source

REQUIREMENTS FOR EFFICIENT PCR CLAMPING BY LOCKED NUCLEIC ACID OLIGONUCLEOTIES FOR SIMPLE AND SENSITIVE DETECTION OF SOMATIC MUTATIONS

Сибирский онкологический журнал, 2018
PCR clamping/wild-type blocking PCR with non-extendable locked nucleic acid (LNA) oligonucleotides is used for sensitive detection of somatic mutations in tumors.
V. A. Shamanin, I. V. Karpov, E. E. Pisareva, N. I. Gutkina, S. P. Kovalenko   +4 more
doaj   +1 more source

Current Advance in Targeted Treatment and Immunotherapy for BRAF-mutant 
Advanced Non-small Cell Lung Cancer

Chinese Journal of Lung Cancer, 2021
With the development of precision medicine, therapies of targeting driver genes have significantly prolonged survival in advanced non-small cell lung cancer (NSCLC) patients.
Na LI, Yanjun XU, Yun FAN
doaj   +1 more source

Targeting Oncogenic BRAF: Past, Present, and Future. [PDF]

, 2019
Identifying recurrent somatic genetic alterations of, and dependency on, the kinase BRAF has enabled a "precision medicine" paradigm to diagnose and treat BRAF-driven tumors.
Bivona, Trever G, Wu, Wei, Zaman, Aubhishek   +2 more
core   +1 more source

Molecular Pathways and Mechanisms of BRAF in Cancer Therapy.

Clinical Cancer Research, 2022
With the identification of activating mutations in BRAF across a wide variety of malignancies, substantial effort was placed in designing safe and effective therapeutic strategies to target BRAF.
Poulikos I. Poulikakos, R. Sullivan, R. Yaeger   +2 more
semanticscholar   +1 more source